Lunaphore Announces Appointment of Matthias Weber, Former President of Leica Biosystems, to Board of Directors
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Matthias Weber, former President of Leica Biosystems, to its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005627/en/
Matthias Weber - The new member of Lunaphore’s Board of Directors (Photo: Business Wire)
Mr. Weber brings extensive experience in the cancer diagnostics and immunohistochemistry fields, marked by excellence in a range of diverse strategic roles including Product Management, R&D, Operations, Sales & Marketing, and most notably as President at Leica Biosystems, a position which he held between 2012 and 2019.
Mr. Weber commented: “I am delighted to join Lunaphore’s Board and to be part of a great team of innovators that will change the future of Immunohistochemistry (IHC) and Cancer Diagnostics”, and he added: “especially in the field of immuno-oncology, the Lunaphore high-plex staining technology offers researchers unique opportunities to simultaneously identify multiple markers while preserving the morphology of the tissue and cells.”
With this appointment, Lunaphore aims to strengthen its position in the field of spatial biology. Mr. Weber’s expert engagement will be instrumental in assisting the efforts to consolidate the company as a leading provider of innovative solutions for immuno-oncology research and tissue analysis.
Lunaphore’s Chairman of the Board, Joe Bernardo, said: “I am excited to have Matthias Weber, MD join our Board. Matthias is a great business leader with global experience at GE Healthcare and Danaher. The knowledge acquired during his 7 years at the helm of Leica Biosystems, a global leader in Anatomical Pathology and especially in Immunohistochemistry, will help us to fully exploit the company’s potential by supporting Lunaphore with the creation of a world class network of KOLs, providing guidance to achieve successful instrument launches into global markets and building strategic partnerships”.
About Mr. Weber
Matthias Weber is an international executive with more than 20 years of experience in the Medical Devices and Diagnostics industries. He is a Medical Doctor (MD; PhD) by training, and has professional experience in Cardiology, successively leading positions in Product Management, R&D, Operations and Sales & Marketing. Since 2004 global P&L responsibility with multiple global locations. From 2012 until 2019 he was the President of Leica Biosystems, a leading $1B Cancer Diagnostics company with extensive presence in the Immunohistochemistry (IHC) space.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of spatial biology in cancer research and tissue analysis through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of accelerating spatial biology and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005627/en/
Contact information
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Théophile Mounier
Lunaphore Corporate Finance
Email: theophile.mounier@lunaphore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 18:41:00 EET | Press release
On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom